Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates

by Olszynski, Wojciech P., Adachi, Jonathan D., Davison, K. Shawn
Published 2014

A critical review of brand and generic alendronate for the treatment of osteoporosis

by Brown, Jacques P, Davison, Kenneth S, Olszynski, Wojciech P, Beattie, Karen A, Adachi, Jonathan D
Published 2013

Evaluation of easily measured risk factors in the prediction of osteoporotic fractures

by Bensen, Robert, Adachi, Jonathan D, Papaioannou, Alexandra, Ioannidis, George, Olszynski, Wojciech P, Sebaldt, Rolf J, Murray, Timothy M, Josse, Robert G, Brown, Jacques P, Hanley, David A, Petrie, Annie, Puglia, Mark, Goldsmith, Charlie H, Bensen, W
Published 2005

The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women

by Adachi, Jonathan D, Ioannidis, George, Olszynski, Wojciech P, Brown, Jacques P, Hanley, David A, Sebaldt, Rolf J, Petrie, Annie, Tenenhouse, Alan, Stephenson, Gregory F, Papaioannou, Alexandra, Guyatt, Gordon H, Goldsmith, Charlie H
Published 2002

Fracture risk prediction: importance of age, BMD and spine fracture status

by Krege, John H, Wan, Xiaohai, Lentle, Brian C, Berger, Claudie, Langsetmo, Lisa, Adachi, Jonathan D, Prior, Jerilynn C, Tenenhouse, Alan, Brown, Jacques P, Kreiger, Nancy, Olszynski, Wojciech P, Josse, Robert G, Goltzman, David
Published 2013

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

by McClung, Michael R., Benhamou, Claude-Laurent, Man, Zulema, Tlustochowicz, Witold, Zanchetta, Jose R., Eusebio, Rachelle, Balske, Ana M., Matzkin, Ellen, Olszynski, Wojciech P., Recker, Robert, Delmas, Pierre D.
Published 2012